CYP3A5 and ABCB1 Polymorphisms and Tacrolimus Pharmacokinetics in Renal Transplant Candidates: Guidelines from an Experimental Study
Open Access
- 1 November 2006
- journal article
- Published by Elsevier BV in American Journal of Transplantation
- Vol. 6 (11), 2706-2713
- https://doi.org/10.1111/j.1600-6143.2006.01518.x
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Contribution of CYP3A5 to the in Vitro Hepatic Clearance of TacrolimusClinical Chemistry, 2005
- The Pharmacogenetics of Calcineurin Inhibitors: One Step Closer Toward Individualized Immunosuppression?Pharmacogenomics, 2005
- ABCB1 Genotype of the Donor but Not of the Recipient Is a Major Risk Factor for Cyclosporine-Related Nephrotoxicity after Renal TransplantationJournal of the American Society of Nephrology, 2005
- Pharmacokinetic Considerations Relating to Tacrolimus Dosing in the ElderlyDrugs & Aging, 2005
- MDR1 haplotypes derived from exons 21 and 26 do not affect the steady‐state pharmacokinetics of tacrolimus in renal transplant patientsBritish Journal of Clinical Pharmacology, 2004
- The Influence of Pharmacogenetics on the Time to Achieve Target Tacrolimus Concentrations after Kidney TransplantationAmerican Journal of Transplantation, 2004
- The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patientsPharmacogenetics, 2004
- A genetic test for immunosuppressant dose selection?Pharmacogenetics, 2004
- Impact of cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients1 2Transplantation, 2003
- Clinical Pharmacokinetics of TacrolimusClinical Pharmacokinetics, 1995